Annual report pursuant to Section 13 and 15(d)

Stock-based Compensation, Stock Option Plan Activity (Details)

v3.23.1
Stock-based Compensation, Stock Option Plan Activity (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Feb. 22, 2021
Nov. 30, 2020
Dec. 31, 2019
Ocuphire Stock Options [Abstract]            
Stock based compensation $ 1,807,000 $ 1,914,000        
Inducement Plan [Member]            
Ocuphire Stock Options [Abstract]            
Common stock reserved for issuance (in shares)       325,258    
2020 Equity Incentive Plan [Member]            
Ocuphire Stock Options [Abstract]            
Common stock reserved for issuance (in shares)         1,000,000  
Percentage of common stock shares outstanding 5.00%          
2020 Equity Incentive Plan [Member] | Maximum [Member]            
Ocuphire Stock Options [Abstract]            
Common stock reserved for issuance (in shares)         70,325  
Period of shares reserved under plan 10 years          
2018 Equity Incentive Plan [Member]            
Ocuphire Stock Options [Abstract]            
Common stock reserved for issuance (in shares) 0         1,175,000
Weighted Average Exercise Price [Abstract]            
Aggregate intrinsic value, outstanding $ 59,000 $ 345,000        
Weighted average fair value per share of options granted (in dollars per share) $ 3.29 $ 3.49        
2018 Equity Incentive Plan [Member] | Minimum [Member]            
Ocuphire Stock Options [Abstract]            
Vesting period 5 months          
2018 Equity Incentive Plan [Member] | Maximum [Member]            
Ocuphire Stock Options [Abstract]            
Vesting period 48 months          
Ocuphire Stock Options [Member] | 2018 Equity Incentive Plan [Member]            
Ocuphire Stock Options [Abstract]            
Stock based compensation $ 1,700,000 $ 1,800,000        
Number of Options [Roll Forward]            
Outstanding, beginning balance (in shares) 2,096,836 1,784,198        
Granted (in shares) 893,305 420,300        
Exercised (in shares) (24,309) (73,442)        
Forfeited/Cancelled (in shares) (29,788) (34,220)        
Outstanding, ending balance (in shares) 2,936,044 2,096,836 1,784,198      
Vested and expected to vest (in shares) 2,936,044          
Vested and exercisable (in shares) 1,723,792          
Weighted Average Exercise Price [Abstract]            
Outstanding, beginning balance (in dollars per share) $ 2.97 $ 2.17        
Granted (in dollars per share) 2.64 5.72        
Exercised (in dollars per share) 1.09 0        
Forfeited/Cancelled (in dollars per share) 6.21 0        
Outstanding, ending balance (in dollars per share) 2.87 $ 2.97 $ 2.17      
Vested and expected to vest (in dollars per share) 2.87          
Vested and exercisable (in dollars per share) $ 2.56          
Weighted average remaining contractual term, outstanding 7 years 9 months 25 days 8 years 2 months 12 days 8 years 10 months 13 days      
Weighted average remaining contractual term, vested and expected to vest 7 years 9 months 25 days          
Weighted average remaining contractual term, vested and exercisable 7 years 25 days          
Aggregate intrinsic value, outstanding [1] $ 3,314,000 $ 2,795,000 $ 7,744,000      
Aggregate intrinsic value, vested and expected to vest [1] 3,314,000          
Aggregate intrinsic value, vested and exercisable [1] $ 1,680,000          
Aggregate intrinsic value (in dollars per share) $ 3.53 $ 3.73        
Weighted average fair value per share of options granted (in dollars per share) $ 2.06 $ 4.36        
[1] The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of December 31, 2022 and 2021 of $3.53 and $3.73 per share, respectively.